Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
Annemarie B van der Aart-van der BeekDaniel H van RaalteCristian GujaKlaas HoogenbergLisa J SuchowerElise HardyC David SjöströmHiddo J Lambers HeerspinkPublished in: Diabetes, obesity & metabolism (2020)
Exenatide once weekly reduced uACR in patients with type 2 diabetes and elevated albuminuria compared to commonly used glucose-lowering drugs.